OCGN - NASDAQ
Ocugen, Inc.
$1.34
-5.1%Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
At a Glance
Live Snapshotocgn
Total Assets
Last Annual Value
43.52M
3-Year CAGR
-26%
5-Year CAGR
10%
10-Year CAGR
2%
Ocugen, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Ocugen, Inc. NASDAQ:OCGN | 43.52M | -12.3% | -16.3% | 1.9% | |
 Compass Therapeutics, Inc. NASDAQ:CMPX | 219.59M | 11.9% | 7.4% | N/A | |
 Alumis Inc. Common Stock NASDAQ:ALMS | 411.94M | 66.3% | N/A | N/A | |
 Lineage Cell Therapeutics, Inc. AMEX:LCTX | 112.58M | 3.7% | -8.4% | -2.3% | |
 Neurogene Inc. NASDAQ:NGNE | 288.60M | 9.0% | 23.2% | 6.5% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 191.05M | -27.3% | -14.9% | N/A | |
 Omeros Corporation NASDAQ:OMER | 325.63M | -4.9% | -4.9% | 17.1% | |
 Fulcrum Therapeutics, Inc. NASDAQ:FULC | 366.28M | 12.4% | 9.3% | N/A | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 240.32M | 11.5% | 3.9% | N/A | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 184.99M | -6.9% | 6.2% | -9.0% |
Ocugen, Inc. Fair Value Envelope
Related Guides
Continue your OCGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.